Satellos Bioscience Inc(MSLE) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 28 at 4:00 PM ET (Korea 10/29 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.98 | Insider Own | 27.85% | Shs Outstand | 20.8M | Perf Week | -2.99% |
| Market Cap | 0.14B | Forward P/E | - | EPS next Y | -2.06% | Insider Trans | - | Shs Float | 15.3M | Perf Month | -24.42% |
| Enterprise Value | 0.08B | PEG | - | EPS next Q | -0.6 | Inst Own | 28.77% | Short Float | 0.64% | Perf Quarter | -32.71% |
| Income | -0.03B | P/S | - | EPS this Y | -38.9% | Inst Trans | -0.01% | Short Ratio | 2.38 | Perf Half Y | -10.59% |
| Sales | 0.00B | P/B | 2.26 | EPS next 5Y | -12.18% | ROA | -64.76% | Short Interest | 0.10M | Perf YTD | 10.54% |
| Book/sh | 2.87 | P/C | 2.23 | EPS past 3/5Y | 16.48% 36.03% | ROE | -70.45% | 52W High | -51.47% ($13.39) | Perf Year | 1.32% |
| Cash/sh | 2.91 | P/FCF | - | Sales past 3/5Y | - | ROIC | -57.77% | 52W Low | 22.58% ($5.30) | Perf 3Y | 87.43% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -6.71% | Gross Margin | - | Volatility(W/M) | 7.16% 7.98% | Perf 5Y | -52.49% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.55 | Perf 10Y | -9.72% |
| Dividend Ex-Date | - | Quick Ratio | 11.22 | EPS Q/Q | -43.13% | Profit Margin | - | RSI (14) | 36.05 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 11.22 | Sales Q/Q | - | SMA20 | -8.64% ($7.11) | Beta | 1.61 | Target Price | $22.09 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/13 | SMA50 | -22.77% ($8.42) | Rel Volume | 2.02 | Prev Close | $6.88 |
| Employees | 18 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -8.53% - | SMA200 | -23.46% ($8.49) | Avg Volume(3M) | 0.04M | Price | $6.5 |
| IPO | 2009/2/19 | Option/Short | No/Yes | Trades | 494 | Volume | 82,518 | Change | -5.52% |
Satellos Biosciences is a clinical-stage biotechnology company founded in Canada in 2018 that develops therapeutics for degenerative muscle diseases by restoring the natural regenerative mechanism of muscle stem cells. Leveraging its proprietary discovery platform, the company is advancing an oral small-molecule candidate into clinical stages for the treatment of Duchenne muscular dystrophy, while continuing its research and development activities primarily in North America.
Over the past 1 year, on the lower side
51% below its 1-year high.
Traded more than usual. That is 202% of its average volume.
MSLE has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -38.9% this year.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -52.5%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 28.8%.
Tap to view numbers
It ranks #334 of 594 in the industry
Based on market cap of $138M.
CMPX#332 Compass Therapeutics Inc $140M PER - 
CDXS#333 Codexis Inc $138M PER - MSLE#334 Satellos Bioscience Inc $138M PER - 
MOLN#335 Molecular Partners AG ADR $136M PER - 
SPRB#336 Spruce Biosciences Inc $135M PER - 
FAQ
What kind of company is MSLE?
MSLE belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of MSLE?
The market cap of MSLE is approximately $138M, ranking 4,288 within its sector.
What is the 52-week high and low for MSLE?
MSLE has recorded a 52-week high of $13.39 and a low of $5.30.
